



# Translational Psychiatry: Light in the Darkness

Translational Psychiatry serves as the vital bridge between laboratory science and the clinician's office. Its central mission is to convert discoveries about brain function at the molecular, cellular, or genetic level into effective, real-world treatments for mental health disorders. In essence, it is the journey from bench to bedside (1,2). Traditional psychiatry has largely depended on the observation of symptoms such as persistent sadness, anxiety, or psychosis to guide diagnosis and treatment. Translational psychiatry seeks to go further, advancing the field toward precision medicine by uncovering the biological mechanisms underlying these symptoms. Rather than asking only what a patient experiences, it asks why those experiences arise (3,4).

## ***This process typically unfolds across four interconnected stages***

**Discovery:** Identifying biological markers such as specific proteins, neural circuits, or gene variants associated with a psychiatric disorder (4,5).

**Development:** Designing drugs, therapies, or interventions that precisely target these biological mechanisms.

**Clinical Trials:** Evaluating these interventions in humans to establish safety, efficacy, and clinical value (6,7).

**Implementation:** Integrating validated treatments into routine clinical practice. The field is advancing rapidly. By early 2026, translational psychiatry has shifted decisively from broad theoretical models toward highly specific, biologically grounded tools, bringing the promise of personalized mental health care closer to reality.

## ***Recent and notable advances***

### **1. New biological targets for psychiatric drugs**

**GluD Receptors:** Delta-type ionotropic glutamate receptors (GluDs) have emerged as promising therapeutic targets. These receptors play a key role in neuronal communication, and genetic mutations affecting them have been linked to anxiety disorders and schizophrenia. Ongoing collaborations between academic researchers and pharmaceutical companies aim to develop drugs that selectively modulate GluD receptor activity when it becomes dysregulated.

**Muscarinic agonists in schizophrenia:** The years 2025–2026 marked a paradigm shift in schizophrenia treatment with the rise of muscarinic receptor agonists. Unlike traditional antipsychotics that primarily

## **Citation to this article**

Akhondzadeh Sh. Translational Psychiatry: Light in the Darkness. *J Iran Med Counc.* 2026;9(2):275-6.

target dopamine pathways, these agents act on alternative neural circuits, improving cognitive function and reducing symptoms while minimizing common side effects.

## 2. The Emergence of metabolic psychiatry

An influential trend in recent years has been the recognition that brain health is deeply intertwined with systemic metabolism.

**The gut–brain protein link:** A February 2026 study revealed that chronic stress reduces levels of Reelin, a protein critical for both intestinal barrier integrity and neural health. This finding suggests that repairing gut dysfunction may directly alleviate depressive symptoms.

**Ketogenic diets as adjunctive therapy:** Recent clinical trials indicate that whole-foods ketogenic diets can significantly improve outcomes in college students with Major Depressive Disorder, functioning as a metabolic “reset” for brain cells and complementing conventional treatments.

## 3. Precision technologies and neuromodulation

**At-Home brain stimulation:** In late 2025, the FDA approved the first wearable, non-pharmacological at-home device for depression. Using mild transcranial direct current stimulation (tDCS), the device targets the prefrontal cortex, expanding access to evidence-based care beyond clinical settings.

**SAINT (accelerated TMS):** Stanford’s Accelerated Intelligent Neuromodulation Therapy has entered broader clinical use. By combining advanced brain imaging with highly individualized targeting, SAINT delivers an intensive course of magnetic stimulation over just five days dramatically shortening the traditional six-week treatment timeline.

## 4. Genetic and RNA-based innovations

**RNA Therapy for Autism:** In early 2025, researchers achieved a successful proof-of-concept for an RNA-based therapy designed to counteract the effects of a specific autism-related gene mutation. This milestone signals a future in which translational psychiatry may move toward preventive, rather than solely symptomatic, interventions.

---

## References

1. de Araújo MB, da Silveira PLS, de Alencar Quirino AH, Andrade AGM, de Matos E Souza FG, Bisol LW. Challenge in translational psychiatry continues: How to find useful biomarkers for psychosis? *Brain Behav Immun* 2024;121:189.
2. Pike AC, Lowther M, Robinson OJ. The Importance of Common Currency Tasks in Translational Psychiatry. *Curr Behav Neurosci Rep* 2021;8(1):1-10.
3. Jafari P, Ghanizadeh A, Akhondzadeh S, Mohammadi MR. Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. *Qual Life Res* 2011;20(1):31-6.
4. Taraz M, Khatami MR, Dashti-Khavidaki S, Akhonzadeh S, Noorbala AA, Ghaeli P, et al. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. *Int Immunopharmacol* 2013;17(3):917-23.
5. Kouti L, Noroozian M, Akhondzadeh S, Abdollahi M, Javadi MR, Faramarzi MA, et al. Nitric oxide and peroxynitrite serum levels in Parkinson’s disease: correlation of oxidative stress and the severity of the disease. *Eur Rev Med Pharmacol Sci*. 2013;17(7):964-70.
6. Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32(1):145-9.
7. Ghaleiha A, Ghyasvand M, Mohammadi MR, Farokhnia M, Yadegari N, Tabrizi M, et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. *J Psychopharmacol* 2014;28(7):677-85.

**Shahin Akhondzadeh Ph.D., FBPhS**

**Editor in Chief**